| Home | | Inventure Capital | | Team | | Investments | | Portfolio | | News | | Contact |
INVENTURE CAPITAL A/S
Inventure Capital is an early stage venture capital investor focusing on Danish investment opportunities and companies within information technology (ICT) and life science.
Inventure Capital have a significant capital base for early stage investments.
Inventure Capital have a significant capital base for early stage investments.
We believe strongly in syndicating our investments with other Danish and international investors in order to establish a sound basis for creating value in the portfolio companies.
News
08-06-2010
Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214
Holte, Denmark, June 7, 2010
Action Pharma A/S obtained encouraging preliminary blinded results in the second phase II clinical trial (named CS005) with its lead development candidate, AP214.
AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as the lead indication. Read more
Holte, Denmark, June 7, 2010
Action Pharma A/S obtained encouraging preliminary blinded results in the second phase II clinical trial (named CS005) with its lead development candidate, AP214.
AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as the lead indication. Read more
20-04-2010
16-04-2010